Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

October 10, 2017 07:30 ET | Source: Onconova Therapeutics

Onconova Therapeutics to Present Updates at Two Investor Conferences in October

NEWTOWN, Pa., Oct. 10, 2017 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ:ONTX), a Phase 3-stage biopharmaceutical company focused on discovering and developing novel products to treat...
October 04, 2017 08:30 ET | Source: Onconova Therapeutics

Onconova to Host Key Opinion Leader Meeting on Novel Approaches to the Diagnosis and Treatment of Pediatric RASopathies on Wednesday, October 11, in New York City

NEWTOWN, Pa., Oct. 04, 2017 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ:ONTX), a Phase 3-stage biopharmaceutical company focused on discovering and developing novel products to treat...
September 05, 2017 08:30 ET | Source: Onconova Therapeutics

Onconova Therapeutics to Participate in Two Investor Conferences in September

NEWTOWN, Pa., Sept. 05, 2017 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ:ONTX), a Phase 3-stage biopharmaceutical company focused on discovering and developing novel products to treat...
August 15, 2017 07:00 ET | Source: Onconova Therapeutics

Onconova Therapeutics, Inc. Reports Recent Business Highlights and Second Quarter 2017 Financial Results

NEWTOWN, Pa., Aug. 15, 2017 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ:ONTX), a Phase 3 stage biopharmaceutical company focused on discovering and developing novel small molecule drug...
August 08, 2017 08:30 ET | Source: Onconova Therapeutics

Onconova Therapeutics, Inc. to Provide Corporate Update and Second Quarter 2017 Financial Results

NEWTOWN, Pa., Aug. 08, 2017 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ:ONTX), a Phase 3-stage biopharmaceutical company focused on discovering and developing novel products to treat...
July 25, 2017 08:30 ET | Source: Onconova Therapeutics

Onconova Therapeutics Announces Establishment of Collaborative Research and Clinical Programs Evaluating Rigosertib in Pediatric “RASopathies”

Company to highlight approaches for studying rigosertib in multiple rare diseases associated with RAS gene at upcoming scientific conferenceCollaboration with National Cancer Institute (NCI) for...
June 26, 2017 08:30 ET | Source: Onconova Therapeutics

Onconova Therapeutics Presents Rigosertib Data at the 22nd Congress of the European Hematology Association in Madrid

Oral Rigosertib combined with Azacitidine administered to patients with treatment naïve and refractory Acute Myeloid Leukemia and Myelodysplastic Syndromes, demonstrates responses in...
June 13, 2017 08:30 ET | Source: Onconova Therapeutics

Onconova Therapeutics to Present at the BIO International Convention

NEWTOWN, Pa., June 13, 2017 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ:ONTX), a Phase 3 stage biopharmaceutical company focused on discovering and developing novel small molecule drug...
June 05, 2017 08:30 ET | Source: Onconova Therapeutics

Onconova Therapeutics Announces Positive Phase 2 Data in Rigosertib Treated Patients with Second-line Myelodysplastic Syndromes at the American Society of Clinical Oncology Annual Meeting

Bone marrow response to rigosertib was evaluated as a surrogate for survival in this trial of 64 patients who had previously failed Hypomethylating Agent therapy22% of patients achieved marrow...
May 22, 2017 08:30 ET | Source: Onconova Therapeutics

Onconova Announces Multiple Presentations at the 22nd Congress of the European Hematology Association

Clinical and Non-clinical Data Evaluating Oral Rigosertib Plus Azacitidine Combination Therapy SymBio, Onconova’s Partner in Japan, to Present Phase 1 Data Evaluating Oral Rigosertib as a Single...